75 related articles for article (PubMed ID: 30333270)
1. A Clinical Trial on Biological Half Life of Bioactive Protein from Lumbricus rubellus, DLBS1033 in Healthy Volunteers.
Gayatri A; Nafrialdi N; Setiabudy RD; Tjandrawinata RR; Rachman A; Louisa M
Acta Med Indones; 2018 Jul; 50(3):208-214. PubMed ID: 30333270
[TBL] [Abstract][Full Text] [Related]
2. Bioactive protein fraction DLBS1033 containing lumbrokinase isolated from Lumbricus rubellus: ex vivo, in vivo, and pharmaceutic studies.
Tjandrawinata RR; Trisina J; Rahayu P; Prasetya LA; Hanafiah A; Rachmawati H
Drug Des Devel Ther; 2014; 8():1585-93. PubMed ID: 25284988
[TBL] [Abstract][Full Text] [Related]
3. DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities.
Trisina J; Sunardi F; Suhartono MT; Tjandrawinata RR
J Biomed Biotechnol; 2011; 2011():519652. PubMed ID: 21403877
[TBL] [Abstract][Full Text] [Related]
4. Toxicity studies of a bioactive protein with antithrombotic-thrombolytic activity, DLBS1033.
Sukandar EY; Anggadireja K; Sigit JI; Adnyana IK; Tjandrawinata RR
Drug Chem Toxicol; 2014 Jan; 37(1):8-16. PubMed ID: 23834224
[TBL] [Abstract][Full Text] [Related]
5. Tabletting Process of Pellets Containing Bioactive Fraction DLBS1033F Isolated from Lumbricus rubellus: Challenge and Strategy.
Christy G; Tjandrawinata RR; Rachmawati H
Biol Pharm Bull; 2015; 38(12):1843-9. PubMed ID: 26354086
[TBL] [Abstract][Full Text] [Related]
6. Dose dependency of earthworm powder on antithrombotic and fibrinolytic effects.
Kim YS; Pyo MK; Park KM; Hahn BS; Yang KY; Yun-Choi HS
Arch Pharm Res; 1998 Aug; 21(4):374-7. PubMed ID: 9875462
[TBL] [Abstract][Full Text] [Related]
7. [Fibrinolytic enzymes extracted from the earthworm. Lumbricus rubellus: a possible thrombolytic agent].
Mihara H
Nihon Seirigaku Zasshi; 1991; 53(7):231-43. PubMed ID: 1941660
[No Abstract] [Full Text] [Related]
8. The Safety and Tolerability of Lumbrokinase DLBS1033 in Healthy Adult Subjects.
Tjandrawinata RR; Yunaidi DA; Susanto LW
Drug Res (Stuttg); 2016 Jun; 66(6):293-9. PubMed ID: 27011386
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women.
Uszynski M; Klyszejko A; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2000 Dec; 93(2):167-71. PubMed ID: 11074138
[TBL] [Abstract][Full Text] [Related]
10. Effect of DLBS1033 on Functional Outcomes for Patients with Acute Ischemic Stroke: A Randomized Controlled Trial.
Pinzon RT; Tjandrawinata RR; Wijaya VO; Veronica V
Stroke Res Treat; 2021; 2021():5541616. PubMed ID: 33927846
[TBL] [Abstract][Full Text] [Related]
11. Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma.
Montes R; Páramo JA; Anglès-Cano E; Rocha E
Br J Haematol; 1996 Mar; 92(4):979-85. PubMed ID: 8616097
[TBL] [Abstract][Full Text] [Related]
12. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
Holvoet P; de Boer A; Verstreken M; Collen D
Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
16. Purification and proteomic analysis of potent fibrinolytic enzymes extracted from Lumbricus rubellus.
Stephani L; Rahayu P; Retnoningrum D; Suhartono MT; Rachmawati H; Tjandrawinata RR
Proteome Sci; 2023 May; 21(1):8. PubMed ID: 37158880
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
van Iersel T; Stroissnig H; Giesen P; Wemer J; Wilhelm-Ogunbiyi K
Thromb Haemost; 2011 Feb; 105(2):302-12. PubMed ID: 21103657
[TBL] [Abstract][Full Text] [Related]
18. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
